PBYI logo

PUMA BIOTECHNOLOGY INC

PBYINASDAQ
🏆 #2814 by market capEarnings Nov 5 · PostUS Equity
$10.54▼ $0.09 (−0.89%)
Pre-market · at close
🔔
Track PBYI
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.9%
7d▼ 4.6%
14d▲ 7.2%
30d▲ 6.0%
ytd▲ 77.1%
1y▲ 92.9%
🏦Market Cap
$544M
Small Cap
📈Revenue Growth (YoY)
-2.9%
Declining
📊Gross Margin
74.8%
High
💵FCF Margin
17.8%
Healthy
⚖️P/S Ratio
2.4x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$10.51 – $10.76
52-Week Range
$4.58 – $11.50
Volume (shares)
9,552
Avg Volume (shares)
—
Shares Outstanding
51.6M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$228M
Last Q Revenue
$57M
P/E Ratio
20.4
P/S Ratio
2.4x
EPS (TTM)
$0.52
Dividend Yield
—
Dilution (1yr)
+4.3%
PBYI logo

PUMA BIOTECHNOLOGY INC

PBYI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$228M▼ −0.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
74.5%▲ +3.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$37M▲ +20.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$42M▲ +7.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
51.5M▲ +4.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1M▲ +$6M YoY
StockOtter · stockotter.space

About PUMA BIOTECHNOLOGY INC

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.